

# An overview of prevalence, determinants and health outcomes of polypharmacy

Mina Khezrian , Chris J. McNeil, Alison D. Murray and Phyo K. Myint 

*Ther Adv Drug Saf*

2020, Vol. 11: 1–10

DOI: 10.1177/  
2042098620933741

© The Author(s), 2020.  
Article reuse guidelines:  
[sagepub.com/journals-](https://sagepub.com/journals-permissions)  
permissions

**Abstract:** A high rate of polypharmacy is, in part, a consequence of the increasing proportion of multimorbidity in the ageing population worldwide. Our understanding of the potential harm of taking multiple medications in an older, multi-morbid population, who are likely to be on a polypharmacy regime, is limited. This is a narrative literature review that aims to appraise and summarise recent studies published about polypharmacy. We searched MEDLINE using the search terms *polypharmacy* (and its variations, e.g. multiple prescriptions, inappropriate drug use, etc.) in titles. Systematic reviews and original studies in English published between 2003 and 2018 were included. In this review, we provide current definitions of polypharmacy. We identify the determinants and prevalence of polypharmacy reported in different studies. Finally, we summarise some of the findings regarding the association between polypharmacy and health outcomes in older adults, with a focus on frailty, hospitalisation and mortality. Polypharmacy was most often defined in terms of the number of medications that are being taken by an individual at any given time. Our review showed that the prevalence of polypharmacy varied between 10% to as high as around 90% in different populations. Chronic conditions, demographics, socioeconomic and self-assessed health factors were independent predictors of polypharmacy. Polypharmacy was reported to be associated with various adverse outcomes after adjusting for health conditions. Optimising care for polypharmacy with valid, reliable measures, relevant to all patients, will improve the health outcomes of older adult population.

**Keywords:** health outcome, multimorbidity, older adults, polypharmacy

Received: 16 October 2019; revised manuscript accepted: 16 May 2020.

## Introduction

A high rate of polypharmacy, often defined as taking five or more medications, is in part a consequence of the increasing rate of multimorbidity in the ageing population worldwide.<sup>1</sup> This has direct negative unintended consequences. Investigating the effectiveness and safety as well as side effects of new medications is traditionally achieved mainly through randomised controlled trials, where patients with multiple chronic conditions or frailty are usually excluded.<sup>1,2</sup> Therefore, our understanding of the potential harm of taking multiple medications in an older, multi-morbid population, who are likely to be on a polypharmacy regime, is limited. Improvement in evidence to better understand the relationship between polypharmacy and health outcomes


should be a priority to optimise treatment in frail older people with various chronic conditions.<sup>3</sup> For various reasons, polypharmacy has drawn much attention recently. Polypharmacy is reported to be the main risk for ‘potentially inappropriate prescribing (PIP)’, with serious implications for healthcare costs.<sup>4–6</sup> It could be used as a quick quality indicator of medication use in older adults.<sup>7</sup> A prospective cohort study found that patients with polypharmacy (6–10 medications) and excessive polypharmacy ( $\geq 11$  medications) were significantly more likely to be prescribed anticholinergic drugs,<sup>8</sup> which are known to be linked to several adverse health outcomes.<sup>9–11</sup> Observational studies have shown that polypharmacy is associated with increased side effects, harmful drug interactions,

Correspondence to:  
**Mina Khezrian**  
Institute of Medical  
Sciences, Lilian Sutton  
Building, University of  
Aberdeen, Foresterhill,  
Aberdeen AB25 2ZD, UK  
[r03mk17@abdn.ac.uk](mailto:r03mk17@abdn.ac.uk)

**Chris J. McNeil**  
**Alison D. Murray**  
Institute of Medical  
Sciences, University of  
Aberdeen, Foresterhill,  
Aberdeen, UK

**Phyo K. Myint**  
Institute of Applied Health  
Sciences, University of  
Aberdeen, Foresterhill,  
Aberdeen, UK





**Figure 1.** Determinants and outcomes associated with polypharmacy. Most of the proposed predictors and outcomes of polypharmacy are also independently associated with health conditions. ADR, adverse drug reaction; BMI, body mass index.

medication non-adherence, and functional and cognitive decline and frailty.<sup>12</sup> It has also been reported to be associated with other important adverse health outcomes such as increased risk of hospitalisation and mortality.<sup>13</sup>

Although polypharmacy is mostly a consequence of multiple chronic conditions (multimorbidity), there might be other modifiable factors that determine polypharmacy independently of this burden. In addition, the association of polypharmacy and health outcome is a complex relationship. Most outcomes associated with polypharmacy are associated independently with pre-existing multimorbidity. Furthermore, many of these outcomes could also exacerbate the rate of prescription, and therefore it should be considered as a bidirectional relationship (Figure 1). For example, the rate of adverse drug reactions (ADR) is significantly higher in patients taking multiple medications. Counterintuitively, patients might require taking more medications to control or reduce these adverse effects.<sup>14</sup>

In this review, we provide current definitions of polypharmacy. We identify the determinants and prevalence of polypharmacy reported in different studies. Finally, we summarise some of the findings regarding the association between polypharmacy and health outcomes in older adults, with a particular focus on frailty, hospitalisation and mortality.

## Methods

This is a narrative literature review that aims to appraise and to summarise recent studies published about polypharmacy. We searched MEDLINE using the search terms ‘polypharmacy’ (and its variations, for example, multiple prescriptions, inappropriate drug use, etc.) in titles. Systematic reviews and original studies in English published between 2003 and 2018 were included. We screened the titles and abstracts of the eligible studies as well as the citations of the articles retrieved during the first search, and selected studies that aimed to address any of our research questions on the definition, prevalence, determinants and outcomes of polypharmacy. We then classified articles based on the results reported. For the health outcomes, we selected articles that reported on the association of polypharmacy and frailty, hospitalisation and mortality.

## Definition of polypharmacy and excessive polypharmacy

Polypharmacy has no generally accepted definition, though criteria for major and minor polypharmacy have been suggested in the literature. Polypharmacy has been defined using different approaches, including numerical and descriptive methods.

Most often, polypharmacy is defined in terms of the number of medications that are being taken by

an individual at any given time. Many studies have used a numerical method either by using a cut-off point or using a continuous number approach to define polypharmacy. Different cut-off points have been suggested. For example, taking more than four, five or six medications at the same time is categorized as polypharmacy. Though, the most frequent definition that has been used so far is 'taking 5 or more medications concurrently' as polypharmacy and '10 or more medications concurrently' as excessive polypharmacy.<sup>15</sup>

Using a strict cut-off to identify polypharmacy with a view to study the associated health outcomes has raised some concerns. A prospective cohort study showed that the number of drug-related problems was linearly related to the number of medicines used in patients admitted to hospital. This approach accounts for effects of number of medications on a linear scale (e.g. from 1 to 4) and a possible dose response relationship that is not captured through a binary classification.<sup>16</sup>

There are some proposed time-defined methods that considered duration of treatment for diagnose of polypharmacy. 'Taking five or more medications for more than 90 days'<sup>17</sup> or 'five or more medications in 1 month for 6 months or more in a year'<sup>18</sup> are some examples. In a study by Fincke and colleagues,<sup>19</sup> a cumulative and continuous definition was suggested for polypharmacy to allow exploration of various aspects of medication use, such as the effect of chronic medication exposure.

There are a few descriptive only definitions suggested for polypharmacy such as 'patients visiting multiple pharmacies to obtain medications' and 'use of additional medications to correct adverse effects'.<sup>20,21</sup>

It is worth emphasising that taking multiple medications is not necessarily unwise and could be both rational and appropriate in some patients. Therefore, it is important to distinguish between appropriate and inappropriate polypharmacy.<sup>1</sup> Recent studies have suggested a shift towards using the term 'appropriate polypharmacy' rather than simply using the count. By adopting this approach, we would be able to distinguish between the necessary and unnecessary prescription of multiple drugs in older adults and to

justify the outcomes. Different definitions of 'appropriate polypharmacy' have been suggested, but more studies are needed to confirm and validate this approach further.<sup>1,15,22</sup>

### Prevalence of polypharmacy in the elderly

The prevalence of polypharmacy reported in literature varies between 10% to as high as around 90% according to the age group, definition used, healthcare and geographical setting of the study.


A cross-sectional analysis of the Survey of Health, Ageing, and Retirement in Europe (SHARE) database showed that the prevalence of polypharmacy, defined as taking five or more medications concurrently in older adults aged 65 years or more, was between 26.3% and 39.9% among 17 European countries and Israel.<sup>23</sup>

According to 'Stimulating Innovation Management of Polypharmacy and Adherence in the Elderly' (SIMPATY), a European Union (EU) funded project aimed at managing polypharmacy by 2030, around 20% of people age 70–74 years are prescribed 10 or more medicines and the rate of polypharmacy is significantly higher in the most deprived population (Figure 2).<sup>24</sup>


In the UK, prescribing rates continue to increase because of population ageing. A population database analysis of 310,000 adults resident in the Tayside region of Scotland reported that the proportion of adults dispensed 5 or more medications doubled to 20.8%, and the proportion dispensed 10 or more tripled to 5.8% between 1995 and 2010.<sup>3</sup> In another study, analysis of electronic primary healthcare records in Scotland showed that 16.9% of adults were receiving 4–9 medications.<sup>25</sup>

Analysis of the prescription drug data in the United States showed that polypharmacy rate increased from 6.3% to 10.7% from 1999–2000 through 2007–2008 in the population (Figure 3).<sup>26</sup>

In Switzerland, it was reported that polypharmacy prevalence was 11.8%, as defined by regular use of five or more different pharmacologically active medicines among 4938 subjects aged between 40 and 81 years.<sup>27</sup>



**Figure 2.** Percentage of patients prescribed 10 or more medicines (excessive polypharmacy) by age group and deprivation in Scotland [obtained from the SIMPATHY consortium document available at <http://www.simpathy.eu/>].<sup>24</sup>



**Figure 3.** Increasing rate of taking prescription medications in the US [obtained from the US prescription drug data for 2007-2008 available at].<sup>26</sup>

<sup>1</sup>Significant linear trend from 1999-2000 through 2007-2008.

Note: Age adjusted by direct method to the year 2000 projected US population.

Source: CDC/NCHS, National Health and Nutrition Examination Survey.

CDC, Centers for Disease Control and Prevention; NCHS, National Center for Health Statistics; US, United States.

Of 2057 participants (60% female; mean age 81.7 years) who visited the emergency department of a geriatric hospital in Italy, 30.3% were taking 6-9 drugs concomitantly, and excessive polypharmacy ( $\geq 10$  drugs) was presented in 17.8% of the patients.<sup>28</sup>

Between 2010 and 2013, a total of 1,742,336 individuals aged 65 years and older were included and followed until death or by the end of the study in Sweden. The prevalence of polypharmacy (taking five or more medications) was 44.0% and the incidence rate in individuals

without polypharmacy at baseline was 19.9 per 100 person-years.<sup>29</sup>

In an older adult Korean population of 319,185 aged 65 years and older, an 86.4% estimated prevalence of polypharmacy ( $\geq 6$  medications) was found, of whom 44.9% had excessive polypharmacy ( $\geq 11$  medications) and 3.0% were taking  $\geq 21$  medications.<sup>30</sup> Similarly, Chan *et al.* reported that 83.5% of national samples of 11,338 elderly people in Taiwan were categorised as having polypharmacy defined as taking six or more drugs concomitantly.<sup>31</sup>

A health insurance database analysis compared changes in the rate of polypharmacy over 10 years for different age groups and in men *versus* women. They found that the proportion of patients with polypharmacy was highest in the 75–84 years (32.5%) but the change in the number of drugs used was greatest among patients aged 65–74 years (+2.14, 95% CI 2.10–2.19) compared with older age groups. This study also found that men had a higher increase in the number of medications taken compared with women over the follow up period.<sup>7</sup>

Although the prevalence of polypharmacy reported varies significantly in different countries, prescribing rates continue to increase because of the increase in the older adult population and the availability of many more different medications globally.

### Determinants of polypharmacy

Many studies reported poor health as the main reason for occurrence of polypharmacy in older adults.<sup>5,32–35</sup>

Of all the chronic conditions, obstructive pulmonary disease was the factor most strongly associated with both polypharmacy and excessive polypharmacy in a population-based cohort study in Finland.<sup>32</sup> Diabetes, depression, heart disease, hypertension, being breathless and pain were other conditions and symptoms significantly linked with both polypharmacy and excessive polypharmacy in various observational studies.<sup>32,33</sup>

The neutrophil/lymphocyte ratio, a marker of systemic inflammation, was independently related to higher daily drug consumption after adjusting for chronic conditions. Metabolic syndrome, chronic pain, urinary incontinence, increased creatinine levels and reported gastric disturbances were also

significant risk factors for increased number of medications.<sup>36</sup>

According to the Belgian Health Interview Survey, factors most strongly associated with excessive polypharmacy were having at least one contact with a general practitioner in past 2 months and self-reported depression during the last year. This study reported that 90% of patients in the excessive polypharmacy group were taking cardiovascular system medications.<sup>35</sup>

Studies have shown that demographics, socioeconomic circumstances and self-assessed health factors could also be independently associated with polypharmacy.<sup>3,37</sup> A retrospective cohort study reported that polypharmacy participants were significantly older and more frequently obese, had lower educational attainment and were former smokers.<sup>27</sup>

A cohort study of older adults in a primary care setting in Germany, assessed medication use as reported by older patients and compared it with doctor's perceived medication regimens for their respective patients. This study showed that having a medication disagreement between physicians and patients in terms of the regular intake of prescribed drugs was a significant determinant of polypharmacy.<sup>33</sup> Poor self-assessed health, being dependent on instrumental activities of daily living and having a low perceived health were other significant predictors of polypharmacy.<sup>32,33</sup>

Older adults using multi-dose dispensing, a dose administration aid where medications are supplied into one unit for each dose packed in disposable bags,<sup>29,38</sup> were at significantly higher risk of developing incident polypharmacy compared with those receiving ordinary prescriptions. After adjustment for confounders, living in a nursing home was found to be linked with lower risks of incident polypharmacy and incident excessive polypharmacy in a prospective cohort study of older adults.<sup>29</sup>

### Health outcomes associated with polypharmacy

#### *Polypharmacy and frailty*

Frailty is a multidimensional syndrome characterised by a non-resilient state and increased vulnerability in older adults.<sup>39</sup>

Co-existence of multiple chronic diseases is prevalent in frail older people and can significantly increase the use of multiple medications.<sup>40–42</sup> Frailty and polypharmacy are both very prevalent in older adults, although little is known about the impact they might have on each other. In recent years an increasing number of studies have investigated the relationship between frailty and polypharmacy and have tried to explain the mechanisms underlying their association. A recent systematic review about the relationship between polypharmacy and frailty included the results from 25 publications and concluded that polypharmacy could be associated with increased risk of frailty. The casual relationship is still unclear, and it seems to be a bidirectional relationship.<sup>43</sup>

Polypharmacy has been shown to increase the risk of frailty in older adults independently of other risk factors.<sup>44–46</sup> A longitudinal cohort study followed participants over 8 years showed that polypharmacy was associated with higher incidence of frailty in a dose dependent manner.<sup>45</sup>

Co-occurrence of polypharmacy and frailty could increase the risk of poorer health outcomes in older adults. The adjusted association of combined frailty status and polypharmacy with adverse outcome showed that polypharmacy was linked with mortality, incident disability, hospitalisation and emergency department visits in frail and pre-frail, but not in non-frail, elderly.<sup>47</sup>

#### *Polypharmacy and hospitalisation*

A prospective cohort of community dwelling older men investigated the association between polypharmacy, as an indicator of suboptimal medication use, and incident all-cause hospital admissions, and those due to falls, incontinence and delirium. This study showed that the number of medicines used was independently associated with all cause admission to hospital over 4.5 years of follow up.<sup>48</sup>

In the Taiwan Longitudinal Health Insurance Database study, a dose–response relation was found between polypharmacy, all-cause and fracture-specific admission to hospital. The odds for anticholinergic risk scale scores to predict fracture-specific admission to hospital were comparable with polypharmacy in this study.<sup>7</sup>

Polypharmacy and excessive polypharmacy were both independent risk factors for 6-month emergency department return and hospital admission in an observational cohort study conducted in a geriatric hospital in Italy.<sup>28</sup>

Scottish Polypharmacy Guidance reported that up to 11% of unplanned hospital admissions are related to harm from medicines and almost 50% of these are preventable.<sup>1</sup> Several studies have reported the role of polypharmacy in adverse drug reactions with resultant drug-related hospitalisations. A review study by Salvi and colleagues pointed out that polypharmacy, which is often associated with the use of potentially inappropriate prescription, was amongst the main reasons for drug-related hospitalisations in older adults along with other risk factors such as changes in pharmacokinetic and pharmacodynamics with older age and multiple chronic conditions.<sup>49</sup>

Nobili *et al.* examined the relationship between polypharmacy and length of hospital stay, and found that polypharmacy was not related to length of hospital stay though the occurrence of adverse events was a significant predictor of prolonged hospital stay by nearly 4 days.<sup>50</sup>

The rate of unplanned hospitalisation was directly linked to the number of medications, but this association was reduced in patients with several conditions in a retrospective cohort study linking the medication data to national hospital admission data in Scotland. Payne and colleagues showed that multiple prescription was associated with the greatest increased risk of unplanned hospitalisation in those with fewest recorded conditions. This study highlighted the importance of considering polypharmacy in the clinical context for which medications were prescribed.<sup>25</sup>

#### *Polypharmacy and mortality*

A systematic review and meta-analysis of 47 studies demonstrated a significant association between mortality and polypharmacy. When polypharmacy is defined categorically, a dose-response relationship was observed across escalating thresholds for defining polypharmacy using values of one to four medications, five medications, and six to nine medications.<sup>13</sup>

A retrospective cohort study examined the association between polypharmacy and mortality in 12,423 participants' aged 65 years or more in England and Wales over 18 years of follow up. According to this study, the relationship between polypharmacy and mortality changed over time and was different for men and women. Polypharmacy was associated with increased mortality in the short term independently of other confounders reported at baseline. The association remained, although weaker, in women over the medium to long term (5–18 years) but decreased continuously over time in men and become non-significant in the longer term.<sup>51</sup>

The Concord Health and Aging in Men Project aimed to determine an optimal discriminating number of concomitant medications associated with mortality in community-dwelling elderly population. The highest value of Youden Index was obtained for a cut-off of 4.5 medications and for each one increase in number of medications, the adjusted odds ratios was 1.09 [95% confidence interval (CI)=1.04–1.15] for mortality. This study supported the use of five or more medications in the current definition of polypharmacy to estimate the medication-related adverse health outcomes.<sup>52</sup>

## Conclusion

Populations are ageing rapidly all over the world and the study of polypharmacy has become a priority in recent years. Polypharmacy is one of the most significant public health challenges in the elderly and the burden is set to increase as more people suffer from long-term conditions. The necessity for immediate and effective polypharmacy management has been prioritised to decrease the risks and costs of prescriptions. There is a need for larger studies that follow patients throughout life to improve understanding of factors predicting polypharmacy and allow detection of vulnerable people at earlier stages. The negative health outcomes associated with polypharmacy should be considered particularly in frail elderly people.

The association of polypharmacy and poor outcomes could simply represent that polypharmacy is the marker of increased risk and not the primary cause of it.<sup>53,54</sup> Therefore, correct adjustment for chronic illnesses to avoid indication bias

is particularly important to consider.<sup>2</sup> Although most of the studies controlled for the effect of chronic conditions, different co-morbidity indices do not cover all common health conditions, and the severity of chronic disease, which could partly explain some of the observed associations between polypharmacy and poor health outcomes.<sup>48</sup> Therefore, assumptions that polypharmacy represents poor care and is always harmful needs to be reconsidered. It is rational to interpret polypharmacy in the clinical context for the individual patient.<sup>25</sup>

Distinguishing between appropriate and inappropriate polypharmacy is necessary and more studies are needed to apply this approach. The appropriateness of polypharmacy could be identified with relevant indicators.<sup>1,22</sup> According to Scottish Polypharmacy Guidance, polypharmacy could be evaluated in different domains by reviewing 'Aims, Need, Effectiveness, Safety, Cost-effectiveness and Patient centeredness'.<sup>1</sup> Burt and colleagues have recently developed an indicator to measure appropriate polypharmacy applicable in primary care.<sup>22</sup> Use of these indicators in clinical practice could improve policy though, their feasibility and usefulness require further evaluation. Reducing inappropriate polypharmacy can be achieved through various interventions such as educational and regulatory interventions. However, the effectiveness and cost-effectiveness of these interventions to improve health outcomes is still unclear.<sup>5</sup> Optimising care for polypharmacy with valid, reliable measures, relevant to all patients, will improve the health outcomes and reduce substantially the healthcare costs of older adult population.

## Conflict of interest statement

The authors declare that there is no conflict of interest.

## Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Elphinstone Scholarship; the Roland Sutton Academic Trust (RSAT 0032/R/15); the Morningfield Association and the Rabin Ezra Scholarship Trust, which provided salary costs and consumables to MK.

## ORCID iDs

Mina Khezrian  <https://orcid.org/0000-0001-9730-0787>

Phyo K. Myint  <https://orcid.org/0000-0003-3852-6158>

## References

1. Scottish Government Polypharmacy Model of Care Group. *Polypharmacy guidance, realistic prescribing*, 3rd ed. Scotland: Scottish Government, 2018.
2. Fried TR, O'Leary J, Towle V, *et al.* Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. *J Am Geriatr Soc* 2014; 62: 2261–2272.
3. Guthrie B, Makubate B, Hernandez-Santiago V, *et al.* The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. *BMC Med* 2015; 13: 74.
4. Cahir C, Fahey T, Teeling M, *et al.* Potentially inappropriate prescribing and cost outcomes for older people: a national population study. *Br J Clin Pharmacol* 2010; 69: 543–552.
5. Patterson SM, Cadogan CA, Kerse N, *et al.* Interventions to improve the appropriate use of polypharmacy for older people. *Cochrane Database Syst Rev* 2014; 10: CD008165.
6. Cullinan S, O'Mahony D, O'Sullivan D, *et al.* Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients. *Age Ageing* 2016; 45: 115–120.
7. Lu WH, Wen YW, Chen LK, *et al.* Effect of polypharmacy, potentially inappropriate medications and anticholinergic burden on clinical outcomes: a retrospective cohort study. *CMAJ* 2015; 187: E130–E137.
8. Lee EK and Lee YJ. Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia. *Int J Clin Pharm* 2013; 35: 711–718.
9. Myint PK, Fox C, Kwok CS, *et al.* Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study. *Age Ageing* 2015; 44: 219–225.
10. Zia A, Kamaruzzaman S, Myint PK, *et al.* Anticholinergic burden is associated with recurrent and injurious falls in older individuals. *Maturitas* 2016; 84: 32–37.
11. Gamble DT, Clark AB, Luben RN, *et al.* Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population. *Int J Epidemiol* 2018; 47: 625–633.
12. Maher RL, Hanlon J and Hajjar ER. Clinical consequences of polypharmacy in elderly. *Expert Opin Drug Saf* 2014; 13: 57–65.
13. Leelakanok N, Holcombe AL, Lund BC, *et al.* Association between polypharmacy and death: a systematic review and meta-analysis. *J Am Pharm Assoc (2003)* 2017; 57: 729–738.e10.
14. Dagli RJ and Sharma A. Polypharmacy: a global risk factor for elderly people. *J Int Oral Health* 2014; 6: i–ii.
15. Masnoon N, Shakib S, Kalisch-Ellett L, *et al.* What is polypharmacy? A systematic review of definitions. *BMC Geriatr* 2017; 17: 230.
16. Viktil KK, Blix HS, Moger TA, *et al.* Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. *Br J Clin Pharmacol* 2007; 63: 187–195.
17. Narayan SW and Nishtala PS. Associations of potentially inappropriate medicine use with fall-related hospitalisations and primary care visits in older New Zealanders: a population-level study using the updated 2012 beers criteria. *Drugs Real World Outcomes* 2015; 2: 137–141.
18. Franchi C, Cartabia M, Rizzo P, *et al.* Geographical differences in the prevalence of chronic polypharmacy in older people: eleven years of the EPIFARM-elderly project. *Eur J Clin Pharmacol* 2013; 69: 1477–1483.
19. Fincke BG, Snyder K, Cantillon C, *et al.* Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database. *Pharmacoepidemiol Drug Saf* 2005; 14: 121–128.
20. Gillette C, Prunty L, Wolcott J, *et al.* A new lexicon for polypharmacy: implications for research, practice, and education. *Res Social Adm Pharm* 2015; 11: 468–471.
21. Medeiros-Souza P, dos Santos-Neto LL, Kusano LTE, *et al.* Diagnosis and control of polypharmacy in the elderly. *Rev Saude Publica* 2007; 41: 1049–1053.
22. Burt J, Elmore N, Campbell SM, *et al.* Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. *BMC Med* 2018; 16: 91.



23. Midão L, Giardini A, Menditto E, *et al.* Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. *Arch Gerontol Geriatr* 2018; 78: 213–220.
24. Mair A, Fernandez-Llimos F, Alonso A, *et al.* *Polypharmacy management by 2030: a patient safety challenge*. Scotland: The Simplicity Consortium, 2017.
25. Payne RA, Abel GA, Avery AJ, *et al.* Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. *Br J Clin Pharmacol* 2014; 77: 1073–1082.
26. Gu Q, Dillon CF and Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. *NCHS Data Brief* 2010; 42: 1–8.
27. Castioni J, Marques-Vidal P, Abolhassani N, *et al.* Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study. *BMC Health Serv Res* 2017; 17: 840.
28. Salvi F, Rossi L, Lattanzio F, *et al.* Is polypharmacy an independent risk factor for adverse outcomes after an emergency department visit? *Intern Emerg Med* 2017; 12: 213–220.
29. Morin L, Johnell K, Laroche ML, *et al.* The epidemiology of polypharmacy in older adults: register-based prospective cohort study. *Clin Epidemiol* 2018; 10: 289–298.
30. Kim HA, Shin JY, Kim MH, *et al.* Prevalence and predictors of polypharmacy among Korean elderly. *PLoS One* 2014; 9: e98043.
31. Chan DCD, Hao YT and Wu SC. Characteristics of outpatient prescriptions for frail Taiwanese elders with long-term care needs. *Pharmacoepidemiol Drug Saf* 2009; 18: 327–334.
32. Jyrkkä J, Enlund H, Korhonen MJ, *et al.* Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. *Drugs Aging* 2009; 26: 493–503.
33. Junius-Walker U, Theile G and Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. *Fam Pract* 2007; 24: 14–19.
34. Payne RA. The epidemiology of polypharmacy. *Clin Med (Lond)* 2016; 16: 465–469.
35. Walckiers D, Van der Heyden J and Tafforeau J. Factors associated with excessive polypharmacy in older people. *Arch Public Health* 2015; 73: 50.
36. Ersoy S and Engin VS. Risk factors for polypharmacy in older adults in a primary care setting: a cross-sectional study. *Clin Interv Aging* 2018; 13: 2003–2011.
37. Cashion W, McClellan W, Howard G, *et al.* Geographic region and racial variations in polypharmacy in the United States. *Ann Epidemiol* 2015; 25: 433–438.e1.
38. Johnell K and Fastbom J. Multi-dose drug dispensing and inappropriate drug use: a nationwide register-based study of over 700,000 elderly. *Scand J Prim Health Care* 2008; 26: 86–91.
39. Clegg A, Young J, Iliffe S, *et al.* Frailty in elderly people. *Lancet* 2013; 381: 752–762.
40. Marengoni A, Angleman S, Melis R, *et al.* Aging with multimorbidity: a systematic review of the literature. *Ageing Res Rev* 2011; 10: 430–439.
41. Myint PK and Welch AA. Healthier ageing. *BMJ* 2012; 344: e1214.
42. Barnett K, Mercer SW, Norbury M, *et al.* Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012; 380: 37–43.
43. Gutiérrez-Valencia M, Izquierdo M, Cesari M, *et al.* The relationship between frailty and polypharmacy in older people: a systematic review. *Br J Clin Pharmacol* 2018; 84: 1432–1444.
44. Herr M, Robine JM, Pinot J, *et al.* Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. *Pharmacoepidemiol Drug Saf* 2015; 24: 637–646.
45. Veronese N, Stubbs B, Noale M, *et al.* Polypharmacy is associated with higher frailty risk in older people: an 8-year longitudinal cohort study. *J American Med Dir Assoc* 2017; 18: 624–628.
46. Saum KU, Schöttker B, Meid AD, *et al.* Is polypharmacy associated with frailty in older people? results from the ESTHER cohort study. *J Am Geriatr Soc* 2017; 65: e27–e32.
47. Bonaga B, Sánchez-Jurado PM, Martínez-Reig M, *et al.* Frailty, polypharmacy, and health outcomes in older adults: the frailty and dependence in albacete study. *J Am Med Dir Assoc* 2018; 19: 46–52.
48. Beer C, Hyde Z, Almeida OP, *et al.* Quality use of medicines and health outcomes among a cohort of community dwelling older men: an

- observational study. *Br J Clin Pharmacol* 2011; 71: 592–599.
49. Salvi F, Marchetti A, D'Angelo F, *et al.* Adverse drug events as a cause of hospitalization in older adults. *Drug Saf* 2012; 35(Suppl. 1): 29–45.
50. Nobili A, Licata G, Salerno F, *et al.* Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. *Eur J Clin Pharmacol* 2011; 67: 507–519.
51. Richardson K, Ananou A, Lafortune L, *et al.* Variation over time in the association between polypharmacy and mortality in the older population. *Drugs Aging* 2011; 28: 547–560.
52. Gnjidic D, Hilmer SN, Blyth FM, *et al.* Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. *J Clin Epidemiol* 2012; 65: 989–995.
53. Gómez C, Vega-Quiroga S, Bermejo-Pareja F, *et al.* Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). *Gerontology* 2015; 61: 301–309.
54. Wastesson JW, Morin L, Tan ECK, *et al.* An update on the clinical consequences of polypharmacy in older adults: a narrative review. *Expert Opin Drug Saf* 2018; 17: 1185–1196.

Visit SAGE journals online  
[journals.sagepub.com/  
home/taw](http://journals.sagepub.com/home/taw)

 SAGE journals